Beeline Medicines is a clinical-stage biotechnology company developing precision therapies for autoimmune and inflammatory diseases, with a lead program targeting lupus. Its lead candidate, afimetoran, is an oral, once-daily small-molecule inhibitor of TLR7 and TLR8 that has demonstrated positive Phase 2 results in systemic lupus erythematosus. The company is advancing afimetoran toward pivotal development for both systemic and cutaneous lupus.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of people suffer from chronic immune-mediated conditions such as lupus that constrain daily life, drain energy, and put long-term health at risk. Progress in autoimmune and inflammatory disease has been too slow, leaving patients cycling through therapies that inadequately control disease and expose them to debilitating complications and organ damage.
Solution
Beeline Medicines is a clinical-stage biotechnology company developing precision therapies that target the underlying drivers of immune dysfunction. Its lead program, afimetoran, is a selective, oral, once-daily small-molecule inhibitor of TLR7 and TLR8, two endosomal immune receptors central to lupus pathogenesis. In a global Phase 2 trial, afimetoran met its primary endpoint, demonstrating significantly higher SRI-4 response rates versus placebo at Week 48 across all dose groups, along with consistent secondary endpoint improvements. The therapy rapidly suppresses type I interferon signaling, dampens inflammatory cytokine networks, and modulates immune cell activation, with a safety profile consistent with prior studies and no new signals observed. Beeline is advancing afimetoran into pivotal development for both systemic and cutaneous lupus erythematosus.
Target Audience
Primary customers are patients living with systemic lupus erythematosus and cutaneous lupus erythematosus, as well as the rheumatologists and dermatologists who treat them. The company also engages with clinical research sites and healthcare providers involved in lupus care.
Features
- Selective, equipotent small-molecule inhibitor of TLR7 and TLR8 with oral, once-daily administration
- Directly blocks genetically validated upstream drivers of lupus pathology, reducing type I interferon production and pro-inflammatory cytokine release
- Phase 2 data showed higher SRI-4 response rates versus placebo at Week 48 (p<0.001 across all dose groups) with improvements across secondary endpoints
- Demonstrated exploratory efficacy in a Phase 1b study in cutaneous lupus erythematosus
- FDA Fast Track designation for systemic lupus erythematosus granted in May 2025
- Mechanism supports potential reduction in steroid usage and associated organ damage